Industry
153d agoEli Lilly Invests $2.75B in AI Drug Development
The $2.75 billion partnership between Eli Lilly and Insilico Medicine signals a major shift in global drug discovery, blending deep‑learning models with traditional chemistry. By leveraging AI‑driven design, the collaboration aims to slash development timelines and lower costs, potentially accelerating access to life‑saving treatments worldwide.
The Signal
This move underscores confidence in AI, encouraging further investment across the industry.